Gyre Therapeutics, Inc. Number of Operating Segments
Gyre Therapeutics, Inc. (GYRE) reported Number of Operating Segments of 2 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-07
- Gyre Therapeutics, Inc. number of operating segments for the quarter ending 2026-03-31 was 2.00 Segment, a 0.00% change year-over-year.
- Gyre Therapeutics, Inc. number of operating segments for the quarter ending 2025-03-31 was 2.00 Segment, a 0.00% change year-over-year.
- Gyre Therapeutics, Inc. number of operating segments for the quarter ending 2024-03-31 was 2.00 Segment, a 100.00% increase year-over-year.
- Gyre Therapeutics, Inc. number of operating segments for the quarter ending 2023-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Gyre Therapeutics, Inc. number of operating segments for fiscal 2025 was 2.00 Segment, a 0.00% change from fiscal 2024.
- Gyre Therapeutics, Inc. number of operating segments for fiscal 2024 was 2.00 Segment, a 0.00% change from fiscal 2023.
- Gyre Therapeutics, Inc. number of operating segments for fiscal 2023 was 2.00 Segment, a 100.00% increase from fiscal 2022.
- Gyre Therapeutics, Inc. number of operating segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.00 Segment 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 2.00 Segment 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 2.00 Segment 10-K · filed 2026-03-13 | |||
| 2025-09-30 | 2.00 Segment 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | 2.00 Segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 2.00 Segment 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | 2.00 Segment 10-K · filed 2025-03-17 | |||
| 2024-09-30 | 2.00 Segment 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 2.00 Segment 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | 2.00 Segment 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | 2.00 Segment 10-K · filed 2025-03-17 | |||
| 2023-09-30 | 1.00 Segment 10-Q · filed 2023-10-26 | |||
| 2023-06-30 | 1.00 Segment 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | 1.00 Segment 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-30 | |||
| 2022-09-30 | 1.00 Segment 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 1.00 Segment 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 1.00 Segment 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-31 | |||
| 2021-09-30 | 1.00 Segment 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 1.00 Segment 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 1.00 Segment 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-04 | |||
| 2020-09-30 | 1.00 Segment 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 1.00 Segment 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 1.00 Segment 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-02-20 | |||
| 2019-09-30 | 1.00 Segment 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | 1.00 Segment 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | 1.00 Segment 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | 1.00 Segment 10-K · filed 2019-03-08 | |||
| 2018-09-30 | 1.00 Segment 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | 1.00 Segment 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | 1.00 Segment 10-Q · filed 2018-05-03 | |||
| 2017-12-31 | 1.00 Segment 10-K · filed 2018-03-19 | |||
| 2017-09-30 | 1.00 Segment 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | 1.00 Segment 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |